Study on safety of insulin add on therapy and oral hypoglycemic agents (ohgas) in type - II diabetes patients

D. Ashalatha¹, C. Roop kumar¹, K. Prem Raj¹, V. Vani¹, P. Narayana Swamy², Sankara Lakshmikanth³.
¹ Pharm.D V year of Jagan’s institute of pharmaceutical science, spsp Nellore, Andhra Pradesh, India.
² Department of Pharmacy Practice, Jagan’s institute of pharmaceutical science, spsp Nellore, Andhra Pradesh, India.
³ PTO (Senior Technical Assistant), NIN, Telangana, National TB Prevalence Survey, ICMR-NIRT.

ABSTRACT

Objectives: A clinical observational investigation directed to look at the security of Insulin add-on treatment and Hypoglycemic Agents in polypharmacy and to advance safe utilization of insulin and hypoglycemic agents in Type II Diabetes patients, through patient guiding by Clinical drug specialist at Jayabharath hospital, Nellore. 

Methods: A Prospective Observational investigation was directed on Type -2 Diabetes mellitus patients in the General Medicine office in a tertiary consideration emergency clinic, during the time of June – December 2019. The work was completed by utilizing quiet information assortment structures and a Diabetes survey.

Results: Among 193 investigation populace with Type -2 Diabetes, hypoglycemic agents in polypharmacy 46.25% (n=108) was discovered to be more than Insulin alone, and Insulin add on treatment. Conclusion: From the examination, it was discovered that patients who are on hypoglycemic agents in polypharmacy were exposed to GI unsettling influences and who are on Insulin treatment was exposed to hypoglycemic scenes. Considering the key job of drug specialists the security of antidiabetic prescriptions and adherence was improved through patient directing.

INTRODUCTION

Diabetes is a chronic disease, which occurs when the pancreas does not produce enough insulin, or when the body cannot effectively use the insulin that it produces. This leads to an increased concentration of glucose in the blood (hyperglycaemia). The primary objective of diabetes management is to achieve satisfactory levels of glycaemic control, which reduces the risk of associated serious, long-term complications [1, 2]. Literature suggests that the majority of people with type 2 diabetes (T2D) worldwide are not achieving targeted glycemic levels [3]. The T2D is characterised by progressive loss of beta cell function requires concurrent changes in treatment to maintain adequate glycemic control, mostly require insulin therapy to achieve this [4]. Due to distinguished pharmacodynamic and pharmacokinetic profile and based on evidence of their efficacy and safety in clinical trials, now a day's insulin analogues are gaining wide acceptance and are frequently prescribed [5]. Most patients begin treatment with diet and exercise with or without treatment regimen but, unfortunately most patients are unsuccessful in controlling type 2 diabetes through lifestyle modification alone and require antidiabetic agents. In poorly controlled diabetics there is a requirement for intensified and multidrug regimens, ultimately, oral agents alone cannot be the mainstay treatment for glycaemic control in many individuals and therapy must be added by the addition of insulin. Therefore this study is conducted with the aim to compare the safety (adverse effects, contraindications and Drug-Drug interactions) of the two possible approaches i.e OHGAs polypharmacy and insulin add on therapy for managing failure of combination therapy with oral medication only [6].

Figure 01: Standard Treatment Guidelines for Type 2 Diabetes Mellitus
Research Article

Note: The broken line indicates that biguanides or insulin secretagogues, but not glucosidase inhibitors or thiazolidinediones, are preferred for initial therapy [1].

Table 01: Nutrition Therapy for Diabetes Mellitus

| MEDICAL NUTRITION THERAPY |
|---------------------------|
| Nutrition therapy for all patients with diabetes as part of overall treatment plan |

Prediabetes or diabetes Individualized medical nutrition therapy as needed to achieve treatment targets, preferably provided by registered dietitian.

Table 02: Physical Activity in Type II Diabetes Mellitus

| PHYSICAL ACTIVITY |
|--------------------|
| Adults with diabetes |

Exercise programs should include

- ≥ 150 min/wk moderate – intensity aerobic activity (50% - 70% max heart rate), spread over
- ≥ 3 days/wk with no more than 2 consecutive days with out exercise.
- Resistance training ≥ 2 times/wk (in absence of contraindications)

Evaluate patients for contraindications prohibiting certain types of exercise before recommending exercise program.

Consider age and previous level of physical activity.

Children with diabetes/prediabetes - ≥ 60 min physical activity/day.

Table 03: Oral Hypoglycemic Agents

| MEDICATION | MECHANISM OF ACTION | SIDE EFFECTS | CONTRAINDICATIONS |
|------------|---------------------|--------------|-------------------|
| Biguanides | Reduce gluconeogenesis, increase glucose utilisation | Lactic acidosis, anorexia, Vit B12 deficiency, nausea, diarrhoea, GI dyscomfort | Hepatic or renal impairment, alcoholism, advanced age |
| Metformin  |                     |              |                   |
| Sulphonyl ureas | Stimulates release of endogenous insulin | Significant hypoglycaemia, nausea, GI discomfort | Hepatic or renal impairment |
| Glibenclamide | Glimepride | Glipizide Gliclazide | |
| Thiazolidinediones | Increase peripheral | Increased TG, | Liver disease |
| Rosiglitazone Pioglitazone | insulin sensitivity, reduce gluconeogenesis | weight gain, hepatotoxicity, anemia | Congestive heart failure |
| Meglitinides | Repaglinide | Stimulate release of endogenous insulin | Less frequent hypoglycemia | Hypersensitivity |
| Alpha glucosidase inhibitors | Acarbose | Decrease the absorption of carbohydrates | Flatulence, abdominal cramping, diarrhoea | Diabetic ketoacidosis, Hypersensitivity, DKA, IBD |
Table 04: Hypoglycemia Management

| At risk patients | Ask about symptomatic and asymptomatic hypoglycemia at each encounter |
|------------------|------------------------------------------------------------------------|
| Preferred treatment: glucose (15-20 g) | |
| • After 15 mins of treatment, repeat if hypoglycemia continues (per SMBG) | |
| • When SMBG normal: patient should consume meal or snack to prevent recurrence | |
| Prescribe glucagon if significant risk of severe hypoglycemia | |
| Hypoglycemia unawareness or episode of severe hypoglycemia | Reevaluate treatment regimen |
| Insulin-treated patients: raise glycemic targets for several weeks to partially reverse hypoglycemia unawareness and reduce recurrence |
| Low or declining cognition | Continually assess cognitive function with increased vigilance for hypoglycemia. [9] |

A reasonable initial dose is 20 g of glucose. If neuroglycopenia precludes oral feedings, parenteral therapy is necessary. Intravenous glucose (25 g) should be given using a 50% solution followed by a constant infusion of 5 or 10% dextrose. If intravenous therapy is not practical, subcutaneous or intramuscular glucagon can be used, particularly in patients with type 1 diabetes mellitus. Because it acts primarily by stimulating glycogenolysis, glucagon is ineffective in glycogen-depleted individuals (e.g., those with alcohol-induced hypoglycemia). It also stimulates insulin secretion and is therefore less useful in type 2 diabetes mellitus. These treatments raise plasma glucose concentrations only transiently, and patients should be encouraged to eat as soon as practical to replete glycogen stores [7].

AIMS AND OBJECTIVES

AIMS
A clinical observational study on safety of Insulin add on therapy and OHGA poly pharmacy in type 2 diabetic patients attending general medicine ward in Jayabharath hospital, Nellore from June – December 2019.

OBJECTIVES
- To compare safety of insulin add on therapy and Oral hypoglycemic agents poly pharmacy.
- To promote safe use of insulin through patient counseling by clinical pharmacist.

PLAN OF WORK
The work is planned to carry out as following:
- To include type 2 diabetes mellitus patients.
- To design a patient data collection form and diabetes questionnaire.
- To collect all the data required for the study from general medicine ward.
- To analyse the data and provide the feedback of results to the physician (prescriber) and submit the safety data of insulin add on therapy and OHA’s polypharmacy in type-2 DM.
- To counsel the patients regarding the usage of medications.

METHODOLOGY

STUDY SITE
A Non experimental prospective observational study was conducted on type-2 diabetes mellitus patients in general medicine department, JAYABHARATH HOSPITAL, Nellore, Andhra Pradesh.

STUDY PERIOD
The study is being conducted from June – December 2019.

INCLUSION CRITERIA
- Subjects more than 18 years of age with Type II diabetes.
- FBS must be > 130 mg/dl.
- Both inpatients and outpatients who consulted the general medicine department.
- The patients who are willing to participate in the study.

EXCLUSION CRITERIA
- Critically ill patients who cannot participate in the study.
- Subjects with Type I DM.
- Subjects on OHGA monotherapy.
- Patients who are not willing to participate in the study.

STUDY DESIGN
A prospective observational study.

STUDY METHOD
- Study is conducted in Jayabharah Hospital, Nellore, a 300 bedded tertiary care hospital.
- All patients with Type 2 diabetes mellitus will be included in the study.
- Most of the patients visiting the hospital are from rural areas.
- Patients were screened for FBS/RBS/PPBS level and FBS must be > 130 mg/dl were considered.
- Evaluation of clinical symptoms, FBS/RBS/PPBS levels in patients on Insulin add on therapy and OHGA polypharmacy for better glycemic control and adherence, safety parameters were assessed.
Research Article

- The baseline knowledge of the patients on the disease, complications, regular blood glucose monitoring, diet, life style modifications and medication adherence is assessed using a questionnaire.
- Patients are then counseled about disease, diet, life style modifications and medication adherence.
- Patients are reviewed periodically (i.e., every 3 months) for the improvement in their blood sugar levels and improvement in general condition.

RESULTS

Table 05: Current Drug Usage

| Type of drug          | Drug usage in no. persons | % of drug usage |
|-----------------------|---------------------------|-----------------|
| Insulin               | 80                        | 55.95           |
| OHGA's poly pharmacy  | 108                       | 41.45           |
| Insulin addon therapy | 5                         | 2.5             |

Table 06: ADR Occurrence in Different Drug Therapies

| Type of drug                        | Overall ADR occurrence | % ADR occurrence |
|-------------------------------------|-------------------------|------------------|
| Metformin+glibenclamide             | 81                      | 32.92            |
| Metformin+glimipride                | 30                      | 12.19            |
| Triple therapy                      | 6                       | 2.4              |
| Insulin                             | 33                      | 13.41            |
| Insulin add on therapy              | 13                      | 5.28             |

Table 08: % of ADR in Current Treatment

| Drug                          | Total no. exposed | ADR occurrence | % ADR |
|-------------------------------|-------------------|----------------|-------|
| OHGAs polypharmacy            | 116               | 73             | 62.9  |
| Insulin                       | 5                 | 3              | 60    |
| Insulin add on therapy        | 5                 | 2              | 40    |

Table 07: % of ADR in Current Treatment

| Drug                        | Total no. exposed | ADR occurrence | % ADR |
|-----------------------------|-------------------|----------------|-------|
| OHGAs Polypharmacy          | 80                | 37             | 46.25 |
| Insulin                     | 108               | 49             | 45.3  |
| Insulin addon therapy       | 5                 | 2              | 40    |
Research Article

Table 11: ADRS of antidiabetic agents

| Type of ADR  | Polypharmacy | Insulin | Insulin add on therapy |
|--------------|---------------|---------|------------------------|
| Flatulence   | 27.5          | 0       | 16.5                   |
| Dyspepsia    | 30            | 0       | 11                     |
| Nausea/vomiting | 17.5       | 0       | 9                      |
| Diarrhoea    | 12.5          | 0       | 4                      |
| Heart burn   | 12.5          | 0       | 3                      |
| Hypoglycemia | 12.5          | 29.6    | 20                     |

DISCUSSION

A prospective observational study done in a tertiary care hospital during the period of June – December, 2019 in type 2 diabetic patients, on safety of Oral hypoglycaemic agents polypharmacy (OHGAs) and insulin add on therapy to OHGAs and promotion of safe use of antidiabetic medications through patient counseling. The OHGAs to which the patient population exposed currently are combination of metformin and glibenclamide; metformin and glimepride; metformin and gliclizide; metformin, glimepride and pioglitazone; metformin, glimepride and voglibose, insulin alone and insulin add on therapy with OHGAs. Considering the antidiabetic usage currently OHGAs polypharmacy (108 out of 193) was found to be more than insulin alone (80 out of 193) and insulin add on therapy (5 out of 193) responsible increased occurrence of ADRs like flatulence (27.5%), dyspepsia(30%), nausea/vomiting(17.5%), hypoglycemia(12.5%) in OHGAs polypharmacy and flatulence (24%), dyspepsia(16%), nausea/vomiting(13%), diarrhoea(6%) heart burn(12%), hypoglycaemia(29%) in insulin add on therapy. Except hypoglycaemia the occurrence of all other ADRs were comparatively less in patient population on insulin add on therapy than OHGAs polypharmacy.

CONCLUSION

Hence the safety assessment i.e. ADR occurrence, sub therapeutical and toxic responses, adherence to medication were carried out in study population who are on antidiabetic agents like OHGAs polypharmacy, insulin alone, insulin add on therapy considering FBS/ RBS , physical symptoms, questionnaire as evaluating parameters. Considering the key role of pharmacist the safety of antidiabetic medications and adherence was improved through patient counselling on disease, proper drug usage (how to take, when to take, how much to take, how long to take, with what we have to take medication, do’s and don’ts while administering antidiabetic medication, possible side effects and contraindications, advantages of taking medication), diet (daily calorie intake, diet chart, foods to be taken and to be avoided), physical activity (what to do ?, how long to do?) which reduced the ADRs, economical burden with its management and worsening condition due to withdrawl of medication and promoted the quality of life of patient.
REFERENCES

1. King, P.; Peacock, I; Donnelly, R. Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352 (9131), 837–853.

2. Stratton, I. M.; Adler, A. I.; Neil, H. A.; Matthews, D. R.; Manley, S. E.; Cull, C. A.; Hadden, D.; Turner, R. C.; Holman, R. R. Association of Glycaemia with Macrovascular and Microvascular Complications of type 2 Diabetes (UKPDS 35): Prospective Observational Study. BMJ 2000, 321 (7258), 405–412.

3. Del Prato, S.; Felton, A. M.; Munro, N.; Nesto, R.; Zimmet, P.; Zimman, B.; Global Partnership for Effective Diabetes Management Improving Glucose Management: Ten Steps to Get More Patients with type 2 Diabetes to Glycaemic Goal. Recommendations from the Global Partnership for Effective Diabetes Management. Int. J. Clin. Pract. Suppl. 2007, 157 (157), 47–57.

4. Tibaldi, J.; Rakel, R. E. Why, When and How to Initiate Insulin Therapy in Patients with type 2 Diabetes. Int. J. Clin. Pract. 2007, 61 (4), 633–644.

5. Freeman, J. S. Insulin Analog Therapy: Improving the Match with Physiologic Insulin Secretion. J. Am. Osteopath. Assoc. 2009, 109 (1), 26–36.

6. Andayani, T.; Ibrahim, M. I. M.; Asdie, A. H. The Safety of Triple Therapy with Oral Antidiabetics Versus Insulin in Type 2 Diabetes. Asian J. Pharm. Clin. Res. 2010, 3, 201–203.

7. Whiting, D. R.; Guariguata, L.; Weil, C.; Shaw, J. IDF Diabetes Atlas: Global Estimates of the Prevalence of Diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 2011, 94 (3), 311–321.

8. Powers, Harrison’s principles of internal medicine, Chapter 338, Diabetes Mellitus, 17th edition, New York: McGraw Hill; 2008; 2275.

9. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Review AACE Diabetes Care Plan Guidelines. Endocr. Pract. 2011, 17 (2).

10. American Diabetes Association Standards of Medical Care in diabetes—2014. Diabetes Care 2014, 37 (1), S14–S80.

11. Apic, L. C. P. guidelines on diabetes. http://www.japi.org/july2007/IDGM.pdf (accessed 2/9/2020).

12. International Diabetes Federation (IDF) [Internet]. Country Estimates Table 2011. IDF- Diabetes Atlas, 6th ed.

13. Noncommunicable Diseases in the Southeast Asia Region, Situation and Response. http://apps.who.int/iris/PDS_DOCS/B4793.pdf; World Health Organization, 2011 (accessed 2/9/2020).

14. Issue3, December2011, Pages311.Available at: http://www.sciencedirect.com/science/article/pii/S0168822711005912.

15. Chiara di loreto, MD et al, Validation of a Counseling Strategy to Promote the Adoption and the maintenance of physical activity by Type 2 diabetic subjects, diabetes care, volume 26, number 2, 404-408, February 2003.

16. Jaakko tuomilehto, MD,et.al, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, the new England journal of medicine, volume 344, may 3, 2001.

17. Vermeire Eljjeet.al, Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus, The Cochrane library, 2001, issue-1, Published by JohnWiley & Sons, Ltd.

18. Hae Mi Choe, PharmD; Sonya Mitrovich, MD; Proactive Case Management of High-risk Patients With Type 2 Diabetes Mellitus by a Clinical Pharmacist:A Randomized Controlled Trial, American journal of managed care, vol.11, no:4,253-260, april 2005.

19. Marita poskiparta, kirsti kasila, Dietary and physical activity counselling on type 2diabetes and impaired glucose tolerance by physicians and nurses in primary healthcare in Finland, Scandinavian Journal of Primary Health Care, 2006; 24: 206-210.

20. Nadia Rashid Al Mazroui, Mostafa Mohamed Kamal, Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus, British Journal of Clinical Pharmacology, Volume 67, Issue 5, pages 547–557, May 2009.

21. anjay kaul, ann F. Bolger, David Herrington et.al, thiazolidine diones and cardiovascular risks: a science advisory from the American heart association and American college of cardiology foundation, journal of American heart association, February 23, 2010; 121: 1860-1877.

22. Stephen M.setter, pharm D, metformin hydrochloride in the treatment of diabetes mellitus: a clinical review with a focus on dual therapy, clinical therapeutics, volume 25, issue 12, p: 2991-3026, December 2003.

23. Saenz a, fernandez-esteban, metformin monotherapy for type-2 diabetes mellitus, Cochrane library 2005, issue 3.

24. Meenu Rani, ShaileshYadav, Incidence of Hypoglycemia and Other Side Effects in Patients of Type 2 Diabetes Mellitus Treated with Glimepiride versus Glibenclamide,international journal of health sciences and research, p:68-72, Vol4; Issue: 2; February 2014.

25. Markolfhanefeld, MD, PHD, One-year glycemic control with asulfonylurea plus pioglitazone versus asulfonylurea plus metformin in patients with type 2 diabetes, diabetes care, p: 141-147, volume 27, number 1,January 2004.

26. Davidson J, Vextau P, Cucinotta D, Vaz J, Kawamori R. Biphasic insulin aspart 30: literature review ofadverse events associated with treatment. Clinical Therapeutics 2005; 27 (Supplement B): S7 5-S88.

Ashalatha D et al, World Journal of Current Med and Pharm Research., Vol-II, Iss-IV,301-306.